🚨 First Substack drop! $PRTC.L #PRTC PureTech Health 💰Cash runway to 2028+ portfolio of 3 mid & late stage multi-bn dollar assets priced at ZERO. 🚀Why this biotech disconnect screams opportunity: #biotech @SeaportTx @daphnezohar @PureTechH https://t.co/nYNquPPnPZ

Looks like the market is finally waking up to the undeniable value on offer at $DAWN

$DAWN (Day One Biopharmaceuticals) is seriously mispriced. Check out my full deep dive on Substack for the why - it's a compelling setup 🚀 https://t.co/aAj5HS9NW8

Hi 👋 I've started a free to read Substack to write about interesting asymmetric opportunities I spot in the markets (heavy on biotech for now). So far, I've covered two under-the-radar setups that look well-positioned for 2026. Click the link to find out more:

Thanks to @PRVWatch for the heads up 🙏

$JAZZ sold their PRV for $200M - insane value in this market! 🤑🤪🤯(see screenshot from $JAZZ recent investor presentation) Massive read-across to $SPRB Spruce Biosciences (mkt cap $85M): On track for Q1 2026 BLA submission → good chance of receiving the PRV in Q3 2026 (if

$PRTC https://t.co/iTFpD4q9iz

🚨Spruce Biosciences $SPRB Find out why this late stage orphan play looks absurdly priced. Market is sleeping on the potential here. 5 bagger potential🚀 Don't miss this one🔥 Read my full thesis here: https://t.co/eYWAZ1QtFQ

🚨"Avacta currently leading the way in dual-payload PDCs" New must-read article just dropped naming #AVCT as the frontrunner in the hottest new ADC/PDC wave: dual-warheads designed to kill resistance dead. https://t.co/Fq0iopf5BC

The market has no idea PRTC own a decent size stake in Cobenfy. "Cobenfy, possibly the biggest drug of our generation" - Jim Cramer "One new potential indication or data readout on Cobenfy every year for the rest of the decade" - CEO Brsitol Myers

PureTech Health #PRTC Not only are you buying a fundamentally criminally undervalued stock, you are also buying at a historically low price. For those who like technical analysis we are currently sitting on an area of mega demand. This level has not been breached since 2017.

Oh and by the way, PRTC is currently trading at near cash so you effectively get their stake in Cobenfy (launched on the market last year & forecast to be one of the biggest selling drugs in the world)plus their entire pipeline for free. Please find me a more undervalued biotech

Beyond the $100Ms in milestones and royalties yet to come from PureTech's sizeable stake in Cobenfy ($BMY's $14B schizophrenia drug), PureTech's pipeline looks very promising, with plenty of value drivers in the next few years. Here's a snapshot: #PRTC $PRTC

UK biotech investors, can you find me a more undervalued biotech stock than PureTech Health? My view - its wildly undervalued. Take a look over the slides below and tell me if Im right. How much do you think #PRTC is worth? #AVCT #OBX #HVO #PRTC #AZN

Alpha Group knock it out the park again, despite tough trading conditions 🔺Revenue on underlying activities up 23% 🔺Total income (inc interest income) up 18% to £221m 🔺Net cash increased by £40m to £217m 🚀PE < 10 for a high quality growth business is a joke #ALPH

https://t.co/gzENffHTjS

https://t.co/Aa58xBZqoL

The team that invented Cobenfy (1st new schizo med in 50+ yrs) is part of this powerhouse! Seaport Therapeutics, a PureTech founded entity and part-owned by PureTech, is led by former CEO & founder @daphnezohar (now Sr. Advisor at PureTech), and current CEO Steve Paul. END/

🚀 PureTech Health'sgroundbreaking "hub & spoke" model is powered by a world-class board & deep bench of scientific & industry leaders. They've driven the development of 29 therapeutics & therapeutic candidates, incl. 3 FDA approvals, and multi-billion dollar transactions

🤔 The market cap of #PRTC is a complete nonsense given the $400M cash, the potential for hundreds of millions in milestone payments, a large stake in Seaport, and multiple late-stage assets poised to be blockbusters if successful in phase 3. Someone please make this make sense!